Immatics N.V
IMTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.16B
Close$
$-2.33
127.1% downside
Current Fair Value
127.1% downsideOvervalued by 127.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.16 Billion |
|---|---|
| Enterprise Value | $947.72 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.54 |
| Beta | 1.33 |
| Outstanding Shares | 136,680,065 |
Return
| Return on Equity | -50.26% |
|---|---|
| Return on Assets | -41.35% |
| Return on Invested Capital | -53.45% |
Valuation & Multiples
| P/E Ratio | -4.72 |
|---|---|
| PEG | 48.67 |
| Price to Sales | - |
| Price to Book Ratio | 4.3 |
| Enterprise Value to Revenue | 22.68 |
| Enterprise Value to EBIT | -4.14 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
$-0.43
Average shareholder expectationRevenue Estimate
$11.90 M
Average shareholder expectationNext Earnings Call
Expected Date
November 17, 2026
EPS Estimate
$-0.50
Average shareholder expectationRevenue Estimate
$12.47 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 2.7603▲ 276.03% |
|---|---|
| Total Calls | 14,600▼ 35.40% |
| Total Puts | 40,300▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 73.02%▼ 7.34% |
|---|---|
| Total Invested | $1.01B▼ 5.03% |
| Investors Holding | 850% |
ESG Score
No data
About Immatics N.V
2,020 employeesImmatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is th...